UPB

Upstream Bio Inc

Add to Watchlist

Advanced Chart

14.340

+0.71(5.209%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

15.270

Open

13.730

VWAP

Vol

760.55K

Mkt Cap

773.02M

Low

13.590

Amount

EV/EBITDA(TTM)

Total Shares

53.79M

301.83M

EV/OCF(TTM)

P/S(TTM)

Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. It has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.

3 Analyst Rating

-19.80% Downside

Wall Street analysts forecast UPB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for UPB is 11.50 USD with a low forecast of 11.50 USD and a high forecast of 11.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

-19.80% Downside

Current: 14.340

Low

11.50

Averages

11.50

High

11.50

-19.80% Downside

Current: 14.340

Low

11.50

Averages

11.50

High

11.50

JP Morgan

Tessa Romero

Buy

Initiates

$38

2024-11-05

Reason

JP Morgan

Tessa Romero

Price Target

$38

2024-11-05

Initiates

Buy

Reason

JPMorgan initiated coverage of Upstream Bio with an Overweight rating and $38 price target. Upsteam's lead asset is verekitug, a recombinant human IgG1 monoclonal antibody that binds the thymic stromal lymphopoietin receptor to treat severe asthma, chronic rhinosinusinitis with nasal polyps and COPD, the analyst tells investors in a research note. The firm sees verekitug as the sole driver for shares over the mid to long term as the clinical profile matures.

William Blair

Matt Phipps

Buy

Initiates

n/a

2024-11-05

Reason

William Blair

Matt Phipps

Price Target

n/a

2024-11-05

Initiates

Buy

Reason

William Blair initiated coverage of Upstream Bio with an Outperform rating.

TD Cowen

Yaron Werber

Strong Buy

Initiates

n/a

2024-11-05

Reason

TD Cowen

Yaron Werber

Price Target

n/a

2024-11-05

Initiates

Strong Buy

Reason

Piper Sandler

Yasmeen Rahimi

Buy

Initiates

$75

2024-11-05

Reason

Piper Sandler

Yasmeen Rahimi

Price Target

$75

2024-11-05

Initiates

Buy

Reason

Piper Sandler initiated coverage of Upstream Bio with an Overweight rating and $75 price target. The analyst believes Upstream's verekitug has a differentiated mechanism of action that targets the TSLP receptor versus ligand. Accordingly, the TSLP ligand has been de-risked by Tezspire's 2021 approval in severe asthma, which represents a rapidly growing biologic market opportunity of $7.5B, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Upstream Bio Inc (UPB.O) is -4.80, compared to its 5-year average forward P/E of -4.94. For a more detailed relative valuation and DCF analysis to assess Upstream Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.94

Current PE

-4.80

Overvalued PE

-2.00

Undervalued PE

-7.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.03

Current EV/EBITDA

-1.86

Overvalued EV/EBITDA

0.42

Undervalued EV/EBITDA

-8.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

399.20

Current PS

505.63

Overvalued PS

597.92

Undervalued PS

200.47